These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12444495)

  • 1. Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist.
    Kassack MU; Höfgen B; Decker M; Eckstein N; Lehmann J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Dec; 366(6):543-50. PubMed ID: 12444495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine/serotonin receptor ligands. Part VIII: the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testings.
    Decker M; Schleifer KJ; Nieger M; Lehmann J
    Eur J Med Chem; 2004 Jun; 39(6):481-9. PubMed ID: 15183906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist.
    Hoefgen B; Decker M; Mohr P; Schramm AM; Rostom SA; El-Subbagh H; Schweikert PM; Rudolf DR; Kassack MU; Lehmann J
    J Med Chem; 2006 Jan; 49(2):760-9. PubMed ID: 16420061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor ligands. Part 18: (1) modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists.
    Robaa D; Enzensperger C; Abul Azm Sel D; El Khawass el S; El Sayed O; Lehmann J
    J Med Chem; 2010 Mar; 53(6):2646-50. PubMed ID: 20180564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine/serotonin receptor ligands, part III [1]: synthesis and biological activities of 7, 7'-alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines -- application of the bivalent ligand approach to a novel type of dopamine receptor antagonist.
    Abadi AH; Lankow S; Hoefgen B; Decker M; Kassack MU; Lehmann J
    Arch Pharm (Weinheim); 2002 Aug; 335(8):367-73. PubMed ID: 12397620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.
    Enzensperger C; Kilian S; Ackermann M; Koch A; Kelch K; Lehmann J
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1399-402. PubMed ID: 17188870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residues at the indole-NH of LE300 modulate affinities and selectivities for dopamine receptors.
    Robaa D; Kretschmer R; Siol O; Abulazm SE; Elkhawass E; Lehmann J; Enzensperger C
    Arch Pharm (Weinheim); 2011 Jan; 344(1):28-36. PubMed ID: 21213349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine/serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands.
    El-Subbagh H; Wittig T; Decker M; Elz S; Nieger M; Lehmann J
    Arch Pharm (Weinheim); 2002 Nov; 335(9):443-8. PubMed ID: 12447918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LE300--new results on its ability to antagonize the discriminative stimulus effects of cocaine.
    Decker M; Lehmann J
    Pharmazie; 2006 Mar; 61(3):248-50. PubMed ID: 16599272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.
    Hamacher A; Weigt M; Wiese M; Hoefgen B; Lehmann J; Kassack MU
    BMC Pharmacol; 2006 Sep; 6():11. PubMed ID: 16978403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists.
    Witt T; Hock FJ; Lehmann J
    J Med Chem; 2000 May; 43(10):2079-81. PubMed ID: 10821720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.
    Mohr P; Decker M; Enzensperger C; Lehmann J
    J Med Chem; 2006 Mar; 49(6):2110-6. PubMed ID: 16539400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
    Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
    Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
    Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
    Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
    Schetz JA; Chu A; Sibley DR
    J Pharmacol Exp Ther; 1999 May; 289(2):956-64. PubMed ID: 10215675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and isolation of a natural dopamine D1 receptor antagonist using cell-based assays.
    Yu S; Park JS; Paredes V; Song MC; Baek NI; Lee SI; Lim JS; Cho NY; Yoon J; Baek K
    J Biotechnol; 2010 Feb; 145(3):304-9. PubMed ID: 19963021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel fused pyrrole heterocyclic ring systems as structure analogs of LE 300: Synthesis and pharmacological evaluation as serotonin 5-HT(2A), dopamine and histamine H(1) receptor ligands.
    Rostom SA
    Arch Pharm (Weinheim); 2010 Feb; 343(2):73-80. PubMed ID: 20108267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.